Summary
Other Scenarios:
- TEVA - GE
- TEVA - RHHBY
- GE - AAA
- RHHBY - AAA
| Buyer: | Teva Pharmaceutical Industries Ltd (ADR) (TEVA) | Last Price: | 32.14 | Market Cap.: | 24.47B |
|---|---|---|---|---|---|
| Target: | Altana AG (ADR) (AAA) | Last Price: | 60.77 | Market Cap.: | 8.25B |
Lines of Business Summary:
- Teva Pharmaceutical Industries Ltd (ADR) (TEVA) competes in 1 industry and 491 product/service groups
- Altana AG (ADR) (AAA) competes in 2 industries and 38 product/service groups
- A combined entity will have 2% Product/Service Group overlap
- Teva Pharmaceutical Industries Ltd (ADR) (TEVA) has 0 and Altana AG (ADR) (AAA) has 1 suppliers that rely on a material % of their business. They share 0 in common.
- Teva Pharmaceutical Industries Ltd (ADR) (TEVA) has 0 and Altana AG (ADR) (AAA) has 1 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Healthcare |
|
|
870 |
Biopharmaceuticals |
|
|
330 |
|
Medical Devices |
|
247 | |
|
Nutritional Health |
|
22 | |
|
Outsourced Services |
|
66 | |
|
Veterinary Products and Services |
|
6 | |
|
Manufacturing |
|
1,180 | |
|
Materials |
|
444 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 492)
|
Target (Total: 29)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 9)
|
Target (Total: 6)
|
Buyer (Total: 8)
|
Target (Total: 3)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 14,700 | 4,485 |
| Revenue Per Employee | 623,667.9 | 128,882.7 |
| Total Revenue | 2,285.7 | 414.1 |
| Total Expenses | 1,562.1 | 360.8 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
1,024.0 | 260.4 |
|
SG&A Expense
|
403.8 | 83.8 |
|
Research & Development
|
134.3 | 20.3 |
|
Other Operating Expense
|
0.0 | -3.8 |
|
Operating Income
|
723.6 | 53.4 |
|
Unusual Income
|
0.0 | 0.0 |
|
LT Debt to Capital
|
19.45 | 1.32 |
|
Fwd P/E
|
13.76 | n/a |
|
Fwd P/Rev
|
2.90 | n/a |
| Book Value | 10,578.5 | 2,844.3 |
|
Curr Portion of LTD/Cap Lease
|
0.0 | 373.5 |
Individual Company Summary
Focused
Buyer
Focused ():
*Healthcare > Biopharmaceuticals
Target
Focused ():
*Healthcare > Biopharmaceuticals
Business Description
Buyer
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company producing drugs in all major treatment categories. It is primarily an international generic drug company. Teva also supplies branded products for specific niche categories, such as Copaxone for multiple sclerosis. Teva's active pharmaceutical ingredients (API) business supplies third-party manufacturers, as well as meets its own production requirements. Teva's operations are conducted directly and through subsidiaries in Israel, Europe, North America and several other jurisdictions. During the year ended December 31, 2005, the Company generated approximately 60% of its sales in North America, 29% in Europe and 11% in the rest of the world, predominantly in Israel. On January 26, 2006, Teva completed its acquisition of Ivax Corporation, a multinational generic pharmaceutical company.
Target
ALTANA AG (ALTANA) is a globally operating company that develops, manufactures and markets pharmaceutical and chemical products for a range of targeted, highly specialized applications. The Company operates in two segments: pharmaceuticals and chemicals. ALTANA's pharmaceuticals division develops therapeutics for the global pharmaceuticals markets with a focus on unmet medical needs in the gastrointestinal and respiratory areas. The pharmaceuticals business is mainly driven by Pantoprazole. ALTANA's chemicals division offers a portfolio of specialty chemicals, including additives and measuring instruments, metallic effect pigments and printing inks, coatings and sealing compounds, and electrical insulation coatings for use in a range of downstream applications. On October 1, 2005, ALTANA acquired ECKART GmbH & Co. KG. During the year ended December 31, 2005, it sold its Austrian subsidiary Rembrandtin Lack Ges.m.b.H. In October 2005, the Company acquired Kelstar International.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
50.89 | 50.66 |
|
Operating Margin %
|
10.44 | 13.69 |
|
Quick Ratio
|
1.36 | 1.74 |
|
Current Ratio
|
1.84 | 2.45 |
|
Coverage Ratio
|
-0.14 | 0 |
| Total Assets | 20,005.6 | 4,960.7 |
| Return on Equity % | 3.76 | 7.7 |
| Return on Assets % | 1.99 | 4.42 |
|
Cash+ ST Inv. Per Share
|
2.01 | 1.26 |
| Total Debt | 3,291.3 | 411.6 |
| Total Debt to Equity % | 31.11 | 14.47 |
| Total Debt to Tangible Equity % | 457.19 | 18.86 |
|
Debt to Asset %
|
16.45 | 8.30 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes medical devices that diagnose and treat eye disorders.
|
|
|
|
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
|
|
Manufacturing |
|
|
|
Materials |
|
|
|
Chemicals
The Chemicals Subsector includes companies that manufacture basic, intermediate, specialty, and performance chemicals.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Dermatology |
|
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit the inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Systemic |
|
|
|
Anaphylactic Shock |
|
|
|
Adjunctive Treatments |
|
|
|
Antihistamines/Antiserotonins
Therapeutics that assist the primary treatment of a life-threatening systemic allergic reaction resulting from secondary or subsequent exposure to a foreign substance by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
|
Upper Respiratory |
|
|
|
Anticholinergic Agents
Therapeutics that treat allergic reactions by inhibiting the action of acetylcholine on post-ganglionic nerves as well as smooth muscle.
Buyer Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.
Buyer Products:
Target Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat chest pains by acting on blood vessels to lower blood pressure.
Buyer Products:
|
|
|
|
Arrhythmia |
|
|
|
Adenosine A1 Receptor Agonists
Therapeutics that treat abnormal rhythm of the heart beat by selectively stimulating the A1 adenosine receptor, slowing the speed of AV nodal conduction
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Adjunctive Treatments |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Inotropic/Vasodilatory Agents
Therapeutics that treat acute heart failure by increasing intracellular ionized calcium and contractile force in cardiac muscle and relaxing vascular muscle.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat the ineffective pumping of the heart by acting on blood vessels to lower blood pressure.
Buyer Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Coronary Artery Disease (CAD) |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)/Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking alpha and beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Calcium Channel Blockers
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Buyer Products:
|
|
|
|
Hypotension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat low blood pressure by stimulating alpha adrenergic receptors.
Buyer Products:
|
|
|
|
Peripheral Vascular Disease |
|
|
|
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.
Buyer Products:
|
|
|
|
Stroke |
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that reduce the risk of stroke by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that prevent or treat damage to nerve cells of the brain by preventing platelets from clumping together.
Buyer Products:
|
|
|
|
Phospholipid Precursors
Therapeutics that prevent or treat damage to nerve cells of the brain by inducing new blood vessel formation.
Buyer Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Rosacea |
|
|
|
Emollients
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by moisturizing and softening the skin.
Target Products:
|
|
|
|
Vulgaris |
|
|
|
Antibacterial Agents |
|
|
|
Macrolides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
|
Hair Disorders |
|
|
|
Alopecia (Hair Loss) |
|
|
|
5 Alpha Reductase Inhibitors
Therapeutics that treat hair loss by blocking the action of an enzyme that converts testosterone to a testosterone derivative.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat hair loss by dilating blood vessels.
Buyer Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Chronic Urticaria |
|
|
|
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.
Buyer Products:
|
|
|
|
Dermatitis |
|
|
|
Atopic (Eczema) |
|
|
|
Emollients
Topical therapeutics that soothe and soften the skin.
Target Products:
|
|
|
|
Seborrheic (Dandruff) |
|
|
|
Antifungal Agents |
|
|
|
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.
Target Products:
|
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Buyer Products:
Target Products:
|
|
|
|
Pruritus |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Immunosuppressants
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by suppressing the immune system.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gall Bladder Disorders |
|
|
|
Cholelithiasis (Gallstones) |
|
|
|
Anticholelithic Agents
Therapeutics that treat gall stones by decreasing the liver's cholesterol synthesis and secretion.
Buyer Products:
|
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Ulcer Adhering Agents
Therapeutics that treat peptic ulcers by binding to it and protecting it from further damage.
Buyer Products:
|
|
|
|
Gastric |
|
|
|
Antisecretory Agents
Therapeutics that treat peptic ulcers by preventing the secretion of acid.
Buyer Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Abdominal Gas |
|
|
|
Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the surface tension of gas bubbles in the bowels.
Buyer Products:
|
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Acid Neutralizing Agents
Therapeutics that treat heartburn by neutralizing stomach acid.
Buyer Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Erosive Esophagitis |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Erosive Esophagitis by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Erosive Esophagus by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat Gastroesophageal Reflux Disease (GERD) by blocking dopamine receptor and stimulating gastrointestinal movement without stimulating secretions from the pancreas, stomach or gall bladder.
Buyer Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
Target Products:
|
|
|
|
Gastroparesis |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat gastroparesis by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Impacted Bowels |
|
|
|
Hyperosmotic Agents
Therapeutics that treat constipation by causing fluid overload, which in turn induces liquid stool within a short period of time.
Buyer Products:
|
|
|
|
Stimulants
Therapeutics that treat constipation by stimulating the contraction of bowels by addition of fiber or other substances.
Buyer Products:
|
|
|
|
Stool Softeners
Therapeutics that treat constipation by increasing the absorption of moisture into feces to form a softer body.
Buyer Products:
|
|
|
|
Stool Softeners/Stimulants
Therapeutics that treat constipation by increasing the absorption of moisture into feces to form a softer body as well as stimulating bowel contractions.
Buyer Products:
|
|
|
|
Irregular Bowel Movements |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Stimulants
Therapeutics that treat constipation by stimulating the contraction of bowels by addition of fiber or other substances.
Buyer Products:
|
|
|
|
Stool Softeners/Stimulants
Therapeutics that treat constipation by increasing the absorption of moisture into feces to form a softer body as well as stimulating bowel contractions.
Buyer Products:
|
|
|
|
Diarrhea |
|
|
|
Antiperistaltic Agents
Therapeutics that treat diarrhea by inhibiting the wavelike motion of the digestive tract.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation associated with ulcerative colitis by preventing the accumulation of inflammatory cells like leukocytes and macrophages to the inflammation site.
Buyer Products:
|
|
|
|
Intestinal Intubation |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that cause bowel evacuation prior to intubation by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Rectal Disorders |
|
|
|
Hemorrhoids |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat or suppress inflammation by preventing the accumulation of inflammatory cells like leucocytes and macrophages to the inflammation sites.
Buyer Products:
|
|
|
|
Stomatognathic Disorders |
|
|
|
Toothaches |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat toothache by numbing a localized area.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Hepatitis |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Nucleoside Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Diabetes |
|
|
|
Induced Complications |
|
|
|
Central Diabetes Insipidus |
|
|
|
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.
Buyer Products:
|
|
|
|
Nephropathy |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat hypertension by regulating the blood vessel dilation.
Buyer Products:
|
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.
Buyer Products:
|
|
|
|
Biguanides/Insulin Stimulating Agents
Therapeutics that control high blood sugar by stimulating the release of insulin as well as decreasing the production of glucose in the liver.
Buyer Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Buyer Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitizes organs to insulin.
Buyer Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Cortisols
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Dexamethasones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Prednisones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Buyer Products:
|
|
|
|
Hypoglycemia |
|
|
|
Gluconeogenic Agents/Glycogenolytic Agents
Therapeutics that treat hypoglycemia by enabling the release of glucose from the liver.
Buyer Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Carnitine Deficiency |
|
|
|
Fatty Acid Transporters
Therapeutics that treat the depletion of long-chain fatty acids in the mitochondrial matrix by increasing carnitine level in the plasma, which facilitate the entry of long-chain fatty acids into the mitochondria.
Buyer Products:
|
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventing cyclooxygenase activity.
Buyer Products:
|
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Buyer Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Buyer Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.
Buyer Products:
|
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys and prevent the precipitation of urate in the joint.
Buyer Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds) |
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Parathyroid Gland Disorders |
|
|
|
Hyperparathyroidism (HPT) |
|
|
|
Vitamin D Analogs
Therapeutics that act similar to Vitamin D.
Buyer Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Acromegaly |
|
|
|
Somatostatin Analogs
Therapeutics that prevents the secretion of growth hormones.
Buyer Products:
|
|
|
|
Severe Short Stature |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Buyer Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat abnormal puberty by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Menopause |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Anemia |
|
|
|
Folic Acid Derivatives
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by folic acid deficiency.
Buyer Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercalcemia |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat a disorder characterized by excessive calcium levels by inhibiting the resorption of bone.
Buyer Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds) |
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.
Buyer Products:
|
|
|
|
Hypocalcemia |
|
|
|
Vitamin D Analogs
Therapeutics that treat hypocalcemia by increasing serum levels of calcium, as well as helping the bone calcification process.
Buyer Products:
|
|
|
|
Hypoglycemia |
|
|
|
Gluconeogenic Agents/Glycogenolytic Agents
Therapeutics that treat low blood sugar by promoting the breakdown of glycogen into glucose in the liver as well as the synthesis of glucose from non-carbohydrate precursors.
Buyer Products:
|
|
|
|
Hypokalemia |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.
Buyer Products:
|
|
|
|
Potassium Supplements
Therapeutics that treat hypokalemia by providing potassium to the body.
Buyer Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Thrombocythemia |
|
|
|
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking the action of a pain mediator.
Buyer Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Lupus Erythematosus |
|
|
|
Discoid (DLE) |
|
|
|
Immunosuppressants
Therapeutics that treat an autoimmune disease characterized by disk-shaped skin plaques by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat an autoimmune disease characterized by disk-shaped skin plaques using a steroidal compound.
Buyer Products:
|
|
|
|
Systemic (SLE) |
|
|
|
Immunosuppressants
Therapeutics that treat systemic lupus by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat multiple sclerosis by inhibiting the transformation of deoxyadenosine into deoxyinosine, thereby impairing the proliferation of certain white blood cells.
Buyer Products:
|
|
|
|
Immunomodulators
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths by altering the immune mechanisms.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Immunosuppressants
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Buyer Products:
Target Products:
|
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Lincosamides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
Target Products:
|
|
|
|
Nitroimidazoles
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and causing cell death.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Penicillin Derivatives/Beta-Lactamase Inhibitors
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication and increasing susceptibility to penicillin derived compounds.
Buyer Products:
|
|
|
|
Pseudominic Acids
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and RNA synthesis.
Buyer Products:
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Sulfonamides
Therapeutics that treat a wide variety of bacterial infections by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Aminoglycosides/Polypeptides
Therapeutics that treat dermal infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Cephalosporin Derivatives
Therapeutics that treat bacterial infections of non-skeletal tissue usually involving fat, muscle, and skin by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gingivitis |
|
|
|
Chlorhexidines
Therapeutics that treat inflammation of the gums by causing leakage in bacterial cell walls.
Buyer Products:
|
|
|
|
Heliobacter pylori |
|
|
|
Proton Pump Inhibitors
Therapeutics treat digestive infections caused by Helicobacter pylori bacteria by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Periodontitis |
|
|
|
Tetracyclines
Therapeutics that treat bacterial infections of the gums, teeth, and underlying bone by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone/Joint Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat bacterial infections manifested in the bones or joints by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat bacterial infections of non-skeletal tissue usually involving fat, muscle, and skin by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Conjunctivitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the clear membrane outside the eye preventing the mast cell release of histamine.
Buyer Products:
|
|
|
|
Keratitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the cornea caused by bacterial infection by inhibiting the release of histamine and leukotrienes from mast cells.
Buyer Products:
|
|
|
|
Keratoconjunctivitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the cornea and the clear membrane outside the eye caused by bacterial infection by blocking the release of histamines from mast cells.
Buyer Products:
|
|
|
|
Ocular Infections |
|
|
|
Aminoglycosides/Polypeptides
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis and damaging the cell membrane.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Analgesics/Sodium Channel Blocking Agents
Therapeutics that treat pain associated with infection and inflammation of the middle ear space and ear drum by blocking the movement of sodium ions and thus the initiation and conduction of nerve impulses across the neuronal membrane.
Buyer Products:
|
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the middle ear inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
|
|
|
|
Macrolides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Bronchitis |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting an enzyme vital to bacterial DNA transcription and repair.
Buyer Products:
|
|
|
|
Pharyngitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the cone shaped cavity at the back of the mouth caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Pneumonia |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat inflammation of the lungs caused by bacterial infection by inhibiting folic acid synthesis and bacterial growth.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat infections of the air passage caused by a wide variety of bacteria.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Tonsilitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the lymphoid tissue on either side of the throat caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Prostatitis |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.
Buyer Products:
|
|
|
|
Nitrofurantoins
Therapeutics that treat bacterial infections of the urinary tract by inactivating/altering bacterial proteins and other macromolecules.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Trimethoprim
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by blocking the action of bacterial dihydrofolate reductase.
Buyer Products:
|
|
|
|
Vaginitis |
|
|
|
Lincosamides
Therapeutics that treat inflammation of the mucous membrane of the vagina caused by bacterial infection by inhibiting bacterial protein synthesis.
Target Products:
|
|
|
|
Helminthic |
|
|
|
Ascariasis (Roundworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat helminthic infections by disrupting the cell cycle of the worm.
Buyer Products:
|
|
|
|
Enterobiasis (Pinworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat helminthic infections by disrupting the cell cycle of the worm. itching.
Buyer Products:
|
|
|
|
Hookworms |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections of the intestines.
Buyer Products:
|
|
|
|
Trichuriasis (Whipworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections characterized by large worms attached to the lining of the large intestine.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
Target Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections by increasing permeability of the cell wall causing leakage of cellular contents.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the skin caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
Target Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the skin caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Buyer Products:
|
|
|
|
Onychomycosis (Nail) |
|
|
|
Amine Derivatives |
|
|
|
Allyl
Therapeutics that treat fungal infections of the nail caused by yeast by causing a deficiency in the cell wall.
Buyer Products:
|
|
|
|
Tinea Corporis (Ringworm) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
Target Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by stunting the growth of the branching filaments.
Buyer Products:
|
|
|
|
Tinea Cruris (Jock Itch) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
Target Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the groin and perineum by stunting the growth of the branching filaments.
Buyer Products:
|
|
|
|
Tinea Pedis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
Target Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the feet by stunting the growth of the branching filaments.
Buyer Products:
|
|
|
|
Tinea Versicolor |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
Target Products:
|
|
|
|
Digestive System |
|
|
|
Mucous |
|
|
|
Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the secretory lining of the tissues caused by a yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
Target Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the secretory lining of the tissues caused by a yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Buyer Products:
|
|
|
|
Nervous System |
|
|
|
Cryptococcal Meningitis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Esophageal Candidiasis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Oropharyngeal Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the mucosa caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pahrynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the mucosa caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Vaginal Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Broad Spectrum |
|
|
|
Nitroimidazoles
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Buyer Products:
|
|
|
|
Sulfonamides
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Tetracyclines
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Quinines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by disrupting replication and transcription.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Herpesvirus |
|
|
|
Herpes Simplex Type 1 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Herpes Simplex Type 2 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Varicella Zoster |
|
|
|
Herpes Zoster (Shingles) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause shingles in adults by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Varicella (Chickenpox) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause chicken pox in children by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
RNA Viruses |
|
|
|
Flavivirus |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Nucleoside Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.
Buyer Products:
|
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Buyer Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Buyer Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat inflammation by preventing the accumulation of Substance P at the inflammation sites.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking the action of a pain mediator.
Buyer Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Dementia |
|
|
|
Ergot Alkaloids
Therapeutics that treat dementia by blocking the alpha adrenergic receptors.
Buyer Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Buyer Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Simple |
|
|
|
Adjunctive Therapy |
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat simple partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of calcium into nerve cells.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Akinetic Pattern |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic
Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Myoclonic |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat Grand Mal Seizures by preventing the entrance of sodium into nerve cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat Grand Mal Seizures by modulating the gates which allow sodium into nerve cells.
Buyer Products:
|
|
|
|
Status Epilepticus |
|
|
|
Sodium Channel Modulators
Therapeutics that treat Status Epilepticus by modulating the portal that allows sodium into the nerve cells.
Buyer Products:
|
|
|
|
Headaches |
|
|
|
Chronic |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation by preventing cyclooxygenase activity.
Buyer Products:
|
|
|
|
Tension Type |
|
|
|
Barbiturates/Analgesics/Antipyretics/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons and decreasing pain by inhibiting the production of prostaglandins.
Buyer Products:
|
|
|
|
Barbiturates/Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons as well as decreasing pain by inhibiting the production of prostaglandins.
Buyer Products:
|
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that provide preventative treatments for migraine headaches by inhibiting the uptake of molecules that prevent nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that prevent migraines by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation, as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Motion Sickness |
|
|
|
Anticholinergic Agents
Therapeutics that treat motion sickness by selectively deterring actions of the involuntary nervous system.
Buyer Products:
|
|
|
|
Antivertigo Agents
Therapeutics that prevent the sensation of motion.
Buyer Products:
|
|
|
|
Spasticity (Spinal Shock) |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat spasticity by stimulating the alpha adrenergic receptors.
Buyer Products:
|
|
|
|
Aspartic Receptor Antagonists/Glutamic Receptor Antagonists
Therapeutics that treat Spinal Shock by blocking the receptors for aspartic acid and glutamic acid, both excitatory neurotransmitters.
Buyer Products:
|
|
|
|
Trigeminal Neuralgia (Tic Douloureux) |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat trigeminal Neuralgia by inhibiting the entrance of sodium into the nerve cells.
Buyer Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat multiple sclerosis by inhibiting the transformation of deoxyadenosine into deoxyinosine, thereby impairing the proliferation of certain white blood cells.
Buyer Products:
|
|
|
|
Immunomodulators
Therapeutics that treat multiple sclerosis by changing the actions of the immune system.
Buyer Products:
|
|
|
|
Myasthenia Gravis (MG) |
|
|
|
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.
Buyer Products:
|
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.
Buyer Products:
|
|
|
|
Dopamine Receptor Agonists
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on neurons.
Buyer Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by inhibiting the degradation of neurotransmitters.
Buyer Products:
|
|
|
|
Skeletal Muscle Relaxing Agents/Analgesics
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by relaxing motor muscles and relieving pain.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on the neurons.
Buyer Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by preventing the degradation of neurotransmitters.
Buyer Products:
|
|
|
|
Tourette`s Syndrome |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat the disorder involving uncontrolled verbal outbursts, ticks and facial expressions by blocking dopamine receptors on the neurons.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.
Buyer Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat anxiety by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat anxiety by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat obsessive compulsive disorder by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Childhood/Adolescent Disorders |
|
|
|
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat attention deficit disorder by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.
Buyer Products:
|
|
|
|
Enuresis (Bedwetting) |
|
|
|
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.
Buyer Products:
|
|
|
|
Eating Disorders |
|
|
|
Bulimia |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Lithium-Based Agents
Therapeutics that treat bipolar disorders by decreasing the concentrations of neurotransmitters.
Buyer Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat bipolar disorders by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Depression |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat depression by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat depression by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat depression by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that treat depression by inhibiting the neuronal uptake of serotonin and norepinephrine.
Buyer Products:
|
|
|
|
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Schizophrenia |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Prenatal/Postnatal Nutrition |
|
|
|
Multivitamins
Therapeutics that supplement the nutritional needs of women during pregnancy.
Buyer Products:
|
|
|
|
Prevention (Contraception) |
|
|
|
Contraceptives (Birth Control) |
|
|
|
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Buyer Products:
|
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Buyer Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Endometriosis |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat endometriosis by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Ovarian |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat abnormal puberty by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage breast cancers by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancers by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat breast cancer by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancer by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage breast cancers by inhibiting the production of DNA but are not given with curative intent.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Kaposi`s Sarcoma |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of spindle cells by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Malignant Melanoma |
|
|
|
Alkylating Agents |
|
|
|
Carbazines
Therapeutics that treat Malignant Melanoma by inhibiting RNA and DNA synthesis through the formation of carbonium ions.
Buyer Products:
|
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat cancers of keratinizing epidermal cells by interacting with DNA.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Palliative Agents |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage colorectal cancers without a curative intent by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Folic Acid Derivatives
Therapeutics that treat colorectal cancers by helping to reduce toxicity by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Buyer Products:
|
|
|
|
Gastric Cancer (Stomach Cancer) |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the stomach by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage cancers of the stomach by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Pancreatic Cancer |
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Nitrosoureas
Therapeutics that can cross the blood-brain barrier to treat and manage pancreatic cancers by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage pancreatic cancer without a curative intent by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Endocrinology |
|
|
|
Carcinoid Tumors |
|
|
|
Palliative Agents |
|
|
|
Somatostatin Analogs
Therapeutics that treat and manage a serotonin secreting neoplasm known as a carcinoid tumor by inhibiting the secretion of growth hormone which allows the tumor to grow rapidly.
Buyer Products:
|
|
|
|
Thyroid Gland |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage primary tumors of the thyroid gland by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Head/Neck Cancer |
|
|
|
Localized |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary tumors of the head and neck by interacting with DNA.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphoblastic |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage rapidly progressing cancers of immature lymphocytic cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Lymphocytic |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage rapidly progressing cancers of lymphocytic cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics isolated principally from microorganisms that treat rapidly progressing cancers of lymphocytic cells by interacting with DNA.
Buyer Products:
|
|
|
|
Chronic |
|
|
|
Lymphocytic (CLL) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage slowly progressing cancers of lymphocytic cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by inhibiting the transformation of deoxyadenosine into deoxyinosine thereby impairing DNA synthesis as well as leaving the cancer cells unable to repair single stranded DNA breaks.
Buyer Products:
|
|
|
|
Myeloid |
|
|
|
Acute |
|
|
|
Erythroleukemic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature red blood cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Monocytic |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of mononuclear cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers affecting mononuclear cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Myeloblastic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Myelogenous (AML) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage rapidly progressing cancers of myelogenous cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Promyelocytic (APL) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage promyelocytic leukemia by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Chronic |
|
|
|
Granulocytic |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage slowly progressing cancers of myelocytic cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Myeloblastic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage cancers of immature myeloid cells by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Lymphoma |
|
|
|
Cutaneous T-Cell (CTCL) |
|
|
|
Mycosis Fungoides |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage T-Cell lymphomas of the skin by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Hodgkin`s Disease |
|
|
|
Alkylating Agents |
|
|
|
Carbazines
Therapeutics that treat Hodgkin's Disease by inhibiting RNA and DNA synthesis through the formation of carbonium ions.
Buyer Products:
|
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphomas of B-cells and T-cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat lymphomas of B-cells and T-cells by interacting with DNA.
Buyer Products:
|
|
|
|
Multiple Myeloma (MM) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of mature antibody producing white blood cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone Cancer |
|
|
|
Osteosarcoma |
|
|
|
Palliative Agents |
|
|
|
Folic Acid Derivatives
Therapeutics that are meant to reduce the toxicity of treating malignant tumors of the bone by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Osteolytic Bone Metastases |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat and manage bone cancers that have spread beyond their original tumor site by preventing the loss of bone mass followed by deposition of new bone which can result in entrapped tumors below the new bone surface.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Brain Cancer |
|
|
|
Neuroblastoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancer of primitive ganglion cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat a and manage cancer of primitive ganglion cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Opthalmology |
|
|
|
Retinoblastoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of the retina by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
Target Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Small Cell Lung Cancer (SCLC) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase II, needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Cervical Cancer |
|
|
|
Localized |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary malignanat tumors of the cervix by interacting with DNA.
Buyer Products:
|
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Wilm`s Tumor (Nephroblastoma) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage tumors of the kidney by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage ovarian cancers that have spread beyond their original tumor site by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage ovarian cancers that have spread beyond their original tumor site by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage ovarian cancers by interacting with DNA and inhibiting cell division but are not curative.
Buyer Products:
|
|
|
|
Penile Cancer |
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat cancer of the squamous cells of the penis by interacting with DNA.
Buyer Products:
|
|
|
|
Prostate Cancer |
|
|
|
Localized |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat and manage prostate cancer by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat and manage prostate cancer by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations but are not curative.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of the prostate gland by inhibiting a specific enzyme needed for transcription and replication of DNA but are not curative.
Buyer Products:
|
|
|
|
Testicular Cancer |
|
|
|
Localized |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage primary tumors of the testes by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary tumors of the testes by interacting with DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage testicular cancers that have spread beyond their original tumor site by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage primary tumors of the testes by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Urinary Bladder Cancer |
|
|
|
Papillocarcinoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage mushroom shaped tumors that arise from the inner lining of the bladder by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Transitional Cell Carcinoma |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage cancers arising from the lining of the bladder by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers arising from the lining of the bladder by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Vulvar Cancer |
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat and manage cancers that arise from skin cells of the external female genitalia by interacting with DNA.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Dry Eye |
|
|
|
Lubricants
Therapeutics that wet the eye and lubricate the eye.
Buyer Products:
|
|
|
|
Glaucoma |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that decrease the formation and increase the outflow of the fluid of the eye.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that decrease the formation of the fluid of the eye.
Buyer Products:
|
|
|
|
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.
Buyer Products:
|
|
|
|
Irritation/Inflammation |
|
|
|
Antibacterial Agents (Antibiotics)
Therapeutics that treat infections by inhibiting bacterial replication.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that prevent inflammation by counteracting the histamine protein and by preventing fluid congestion.
Buyer Products:
|
|
|
|
Non-Degenerative Disorders |
|
|
|
Allergic Conjunctivitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat infections by inhibiting the release of chemical mediators from sensitized mast cells.
Buyer Products:
|
|
|
|
Ocular Hypertension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that decrease the formation and increase the outflow of the fluid of the eye.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that decrease the formation of the fluid of the eye.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Acetylcholine Blocking Agents
Therapeutics that inhibit neuromuscular activity by competing with acetylcholine at the cholinergic receptors resulting in neuromuscular blockage.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.
Buyer Products:
|
|
|
|
Primary |
|
|
|
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.
Buyer Products:
|
|
|
|
Reversal |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.
Buyer Products:
|
|
|
|
Local |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat pain by blocking the movement of sodium ions and thus the initiation and conduction of nerve impulses across the neuronal membrane.
Buyer Products:
|
|
|
|
Narcotics |
|
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Non-Narcotics |
|
|
|
Analgesics Combinations |
|
|
|
Analgesics/Antipyretics
Therapeutics that treat pain and fever by inhibiting the action of prostaglandins.
Buyer Products:
|
|
|
|
Analgesics/Antipyretics/Antihistamines
Therapeutics that treat fever and pain by inhibiting the action of prostaglandins, as well as suppressing inflammation.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat pain by inhibiting the reuptake of GABA, which increases the levels of GABA in the synapses.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Buyer Products:
|
|
|
|
Skeletal Muscle Relaxing Agents/Analgesics
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially, as well as prevent inflammation by inhibiting the action of prostaglandins.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat pain by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat pain by inhibiting the accumulation of Substance P at the inflammation site.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the lungs.
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat asthma by inhibiting mast cell degranulation.
Buyer Products:
|
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Buyer Products:
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.
Buyer Products:
Target Products:
|
|
|
|
Bronchitis |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Complications |
|
|
|
Bacterial Infections |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Buyer Products:
|
|
|
|
Bronchospasm |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that are used to prevent COPD attacks by inhibiting the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Target Products:
|
|
|
|
Emphysema |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.
Buyer Products:
|
|
|
|
Respiratory Distress Syndrome (RDS) |
|
|
|
Surfactants
Therapeutics that treat RDS by modifying alveolar surface tension and thereby stabilizing the alveoli.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, and relieving or preventing coughs.
Buyer Products:
|
|
|
|
Decongestants
Therapeutics that treat coughs and colds by reducing mucous build up.
Buyer Products:
|
|
|
|
Decongestants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Decongestants/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.
Buyer Products:
|
|
|
|
Expectorants
Therapeutics that treat coughs and colds by helping in the ejection of mucous.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
General |
|
|
|
Complications |
|
|
|
Nausea/Vomiting |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent post surgical nausea and vomiting through a combination of blocking neurotransmitters and gastrointestinal movement stimulants.
Buyer Products:
|
|
|
|
Neuromuscular Blockage |
|
|
|
Cholinesterase Inhibitors
Therapeutics that reverse neuromuscular blockage by inhibiting the break down of acetylcholine.
Buyer Products:
|
|
|
|
Urinary Retention |
|
|
|
Cholinesterase Inhibitors
Therapeutics that treat urinary retention by preventing the breakdown of acetylcholine resulting in the increased body secretions.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Heavy Metal Poisoning |
|
|
|
Chelating Agents |
|
|
|
Iron
Therapeutics that form chemical complexes with iron and are subsequently excreted.
Buyer Products:
|
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Antihistamines
Therapeutics that treat alcohol withdrawal by blocking the H2 receptors and thus the effects of histamines.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Buyer Products:
|
|
|
|
Transplantation |
|
|
|
Heart |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that help manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
|
Hepatic (Liver) |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
|
Renal (Kidney) |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Penile |
|
|
|
Erectile Dysfunction (Impotence) |
|
|
|
Vasodilatory Agents
Therapeutics that increase blood flow in the penis by dilating blood vessels.
Buyer Products:
|
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.
Buyer Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Buyer Products:
|
|
|
|
Testicular |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat puberty disorders by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Cystitis |
|
|
|
Urotoxin Neutralizing Agents
Therapeutics that inhibit cystis induced by toxic therapeutics by neutralizing these therapeutics.
Buyer Products:
|
|
|
|
Neurogenic Bladder Disease |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat diabetes induced kidney diseases by inhibiting a certain enzyme necessary for regulation of blood pressure.
Buyer Products:
|
|
|
|
Weight Management |
|
|
|
Anorexia (Appetite Loss) |
|
|
|
Progestins
Therapeutics that treat weight loss and other conditions arising from the uncontrolled loss of appetite by administration of hormone progestins.
Buyer Products:
|
|
|
|
Cachexia |
|
|
|
Progestins
Therapeutics that treat cachexia by providing female hormones.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery |
|
|
|
Pulmonary Delivery |
|
|
|
Aerosol Therapy |
|
|
|
Metered Dose |
|
|
|
Dry Powder |
|
|
|
Inhalers (DPI)
Mouthpiece-type of medical devices from which the patients inhale the medication mixture
Buyer Products:
|
|
|
|
Liquid |
|
|
|
Breath Actuated (BAI)
Inhalation devices which are activated by the patients' inspiration
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Treatment |
|
|
|
Dry Eye |
|
|
|
Lubricants
Devices used to alleviate low level of moisture in eye tissue by adding fluid.
Buyer Products:
|
|
|
|
Radiology |
|
|
|
Nuclear |
|
|
|
Gamma Camera |
|
|
|
Contrast Agents |
|
|
|
Radionuclides |
|
|
|
Adjuncts
Radioactive materials that are introduced to the body for nuclear imaging purposes.
Buyer Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
Children`s Health
Products consisting of dietary/naturopathic supplements that are intended to support infants and children's health.
Buyer Products:
|
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
|
|
Men`s Health
Products consisting of dietary/naturopathic supplements that are intended to support men's health.
Buyer Products:
|
|
|
|
Sports Performance/Energy
Products consisting of dietary/naturopathic supplements that are intended to enhance energy level and athletic performance.
Buyer Products:
|
|
|
|
Women`s Health
Products consisting of dietary/naturopathic supplements that are intended to support women's health.
Buyer Products:
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Pharmaceuticals |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Buyer Products:
|
|
|
|
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.
Buyer Products:
|
|
|
|
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.
Buyer Products:
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
|
|
Manufacturing |
|
|
|
Materials |
|
|
|
Chemicals |
|
|
|
Basic and Intermediate Chemicals |
|
|
|
Dyes and Pigments
Includes companies engaged in the manufacturing of dyes and pigments.
Target Products:
|
|
|
|
Specialty and Performance Chemicals |
|
|
|
Additives |
|
|
|
Lubricant Additives
Includes companies engaged in the manufacturing of lubricant additives, chemicals added to lubricants to impart specific beneficial properties or to enhance performance.
Target Products:
|
|
|
|
Other Performance Additives
Includes companies engaged in the manufacturing of other performance additives, chemicals added to a variety of materials to impart specific beneficial properties or to enhance performance.
Target Products:
|
|
|
|
Polymer Additives
Includes companies engaged in the manufacturing of polymer additives, chemicals added to polymers to impart specific beneficial properties or to enhance performance.
Target Products:
|
|
|
|
Adhesives, Sealants, Coatings and Paints |
|
|
|
Adhesives and Sealants |
|
|
|
Building and Construction Adhesives and Sealants
Includes companies engaged in the manufacturing of building and construction adhesives and sealants.
Target Products:
|
|
|
|
Industrial Adhesives and Sealants
Includes companies engaged in the manufacturing of other industrial adhesives and sealants.
Target Products:
|
|
|
|
Coatings and Paints |
|
|
|
Coatings
Includes companies engaged in the manufacturing of coatings used in a wide range of industries.
Target Products:
|
|
|
|
Other Specialty and Performance Chemicals |
|
|
|
Electronic Materials
Materials used to manufacture electronic products such as printed circuit boards. Materials include laminates and specialty foams.
Target Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Novartis AG (ADR)
|
|
n/a | 137,633.808 | 20.06 | 18.92 | 3.80 | 3.74 | 3.57 | |
|
AstraZeneca plc (ADR)
|
|
n/a | 86,846.087 | 14.88 | 14.54 | 3.39 | 3.35 | 8.71 | |
|
Mylan Laboratories Inc.
|
|
n/a | 4,358.526 | 16.83 | 14.75 | 3.21 | 3.03 | 5.75 | |
|
Perrigo Company
|
|
n/a | 1,566.336 | 20.78 | 19.07 | 1.13 | 1.07 | 4.55 | |
|
XenoPort, Inc.
|
|
n/a | 615.282 | n/a | -9.01 | 77.53 | 63.26 | 6.19 | |
|
Taro Pharmaceutical Industries Ltd.
|
|
n/a | 296.106 | 17.07 | 18.80 | 0.98 | 1.01 | 0.77 | |
| Buyer | |||||||||
|
Pfizer Inc.
|
|
n/a | 184,875.794 | 14.65 | 12.47 | 3.83 | 3.83 | 7.92 | |
|
Novartis AG (ADR)
|
|
n/a | 137,633.808 | 20.06 | 18.92 | 3.80 | 3.74 | 3.57 | |
| Target | |||||||||
|
General Electric Company
|
|
n/a | 385,110.639 | 22.41 | 18.29 | 2.42 | 2.29 | 14.85 | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 154,398.687 | 34.26 | 24.41 | 5.58 | n/a | 8.47 | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 149,540.389 | 14.29 | 14.90 | 3.29 | 3.50 | 14.48 | |
|
Novartis AG (ADR)
|
|
n/a | 137,633.808 | 20.06 | 18.92 | 3.80 | 3.74 | 3.57 | |
|
Merck & Co., Inc.
|
|
n/a | 95,524.127 | 18.81 | 17.37 | 4.27 | 4.31 | 5.44 | |
|
AstraZeneca plc (ADR)
|
|
n/a | 86,846.087 | 14.88 | 14.54 | 3.39 | 3.35 | 8.71 | |
|
Tyco International Ltd.
|
|
n/a | 60,341.830 | 16.19 | 14.76 | 1.47 | 1.39 | 11.11 | |
|
BASF AG (ADR)
|
|
n/a | 47,541.928 | 12.18 | 10.62 | 0.74 | 0.91 | 4.45 | |
|
E.I. du Pont de Nemours & Company
|
|
n/a | 44,840.436 | 18.52 | 16.98 | 1.58 | 1.59 | 8.34 | |
|
Bayer AG (ADR)
|
|
n/a | 40,349.508 | 21.74 | 15.71 | 1.06 | 1.09 | n/a | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 24,468.181 | 62.58 | 13.76 | 3.25 | 2.90 | 33.99 | |
|
Hitachi, Ltd. (ADR)
|
|
n/a | 20,363.121 | n/a | -32.67 | 0.24 | 0.24 | 0.99 | |
|
Akzo Nobel N.V. (ADR)
|
|
n/a | 17,297.201 | 10.85 | 15.90 | 0.98 | 0.89 | 3.96 | |
|
Air Products & Chemicals, Inc.
|
|
n/a | 15,717.077 | 21.73 | 18.21 | 1.78 | 1.66 | 4.11 | |
|
PPG Industries, Inc.
|
|
n/a | 10,920.520 | 16.37 | 12.72 | 1.01 | 0.99 | 7.11 | |
|
Imperial Chemical Industries PLC (ADR)
|
|
n/a | 10,436.301 | 17.60 | 15.20 | 0.90 | n/a | n/a | |
|
Mylan Laboratories Inc.
|
|
n/a | 4,358.526 | 16.83 | 14.75 | 3.21 | 3.03 | 5.75 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Biovail Corporation (USA)
|
|
n/a | 3,276.926 | 15.73 | 8.21 | 3.12 | 3.20 | 7.15 | |
|
Watson Pharmaceuticals, Inc.
|
|
n/a | 2,703.106 | 43.01 | 22.76 | 1.52 | 1.44 | 2.39 | |
|
Ness Technologies, Inc
|
|
n/a | 599.398 | 22.21 | 20.22 | 1.34 | 1.27 | 5.98 | |
|
Impax Laboratories Inc.
|
|
n/a | 517.590 | 443.08 | 23.53 | 4.59 | n/a | 8.82 | |
|
I-Many, Inc.
|
|
n/a | 82.690 | n/a | n/a | 2.74 | n/a | n/a | |
|
Antares Pharma, Inc.
|
|
n/a | 61.059 | n/a | n/a | 20.43 | n/a | 16.28 | |
|
BioSante Pharmaceuticals, Inc.
|
|
n/a | 57.897 | n/a | n/a | 116.89 | n/a | 6.41 | |
|
Genelabs Technologies
|
|
n/a | 40.886 | n/a | n/a | 4.37 | n/a | 12.90 | |
|
AutoImmune Inc.
|
|
n/a | 20.304 | n/a | n/a | 62.83 | n/a | 2.31 | |
| Target | |||||||||
|
GPC Biotech AG (ADR)
|
|
97.00% | 711.171 | n/a | n/a | 27.14 | n/a | 7.05 | |
|
3M Company
|
|
n/a | 57,664.827 | 16.78 | 17.35 | 2.57 | 2.54 | 8.88 | |
|
Rockwood Holdings, Inc.
|
|
n/a | 1,891.100 | 23.43 | 17.68 | 0.58 | 0.57 | n/a | |
|
inVentiv Health Inc.
|
|
n/a | 965.894 | 19.15 | 23.73 | 1.32 | 1.28 | n/a | |
|
Nanophase Technologies Corporation
|
|
n/a | 122.512 | n/a | -27.79 | 14.84 | 13.76 | 7.21 | |
|
Bracco S.p.A.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
sanofi-aventis (ADR)
|
|
n/a | 123,912.610 | 32.64 | 14.45 | 3.32 | 3.48 | n/a | |
| Buyer | |||||||||
|
sanofi-aventis (ADR)
|
|
n/a | 123,912.610 | 32.64 | 14.45 | 3.32 | 3.48 | n/a | |
|
Alcon, Inc.
|
|
n/a | 34,053.241 | 32.31 | 27.20 | 7.20 | 7.13 | 16.68 | |
|
Baxter International Inc.
|
|
n/a | 30,464.958 | 24.24 | 21.17 | 3.01 | 2.92 | 7.14 | |
|
Biovail Corporation (USA)
|
|
n/a | 3,276.926 | 15.73 | 8.21 | 3.12 | 3.20 | 7.15 | |
|
XenoPort, Inc.
|
|
n/a | 615.282 | n/a | -9.01 | 77.53 | 63.26 | 6.19 | |
|
Sonus Pharmaceuticals, Inc.
|
|
n/a | 218.218 | n/a | -7.92 | 8.82 | 9.26 | 4.44 | |
|
Novacea, Inc.
|
|
n/a | 151.570 | n/a | -3.20 | 355.80 | 428.42 | 2.27 | |
|
H. Lundbeck A/S
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Wyeth
|
|
11.40% | 68,910.588 | 16.92 | 16.20 | 3.47 | 3.42 | 6.56 | |
|
sanofi-aventis (ADR)
|
|
n/a | 123,912.610 | 32.64 | 14.45 | 3.32 | 3.48 | n/a | |
|
CollaGenex Pharmaceutical, Inc
|
|
n/a | 225.480 | n/a | -6.06 | 14.01 | 9.79 | 10.70 | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
sanofi-aventis (ADR)
|
|
n/a | 123,912.610 | 32.64 | 14.45 | 3.32 | 3.48 | n/a | |
|
Wyeth
|
|
n/a | 68,910.588 | 16.92 | 16.20 | 3.47 | 3.42 | 6.56 | |
| Buyer | |||||||||
|
Johnson & Johnson
|
|
n/a | 192,198.230 | 17.37 | 17.71 | 3.68 | 3.60 | 7.06 | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 149,540.389 | 14.29 | 14.90 | 3.29 | 3.50 | 14.48 | |
|
sanofi-aventis (ADR)
|
|
n/a | 123,912.610 | 32.64 | 14.45 | 3.32 | 3.48 | n/a | |
| Target | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 154,398.687 | 34.26 | 24.41 | 5.58 | n/a | 8.47 | |
|
sanofi-aventis (ADR)
|
|
n/a | 123,912.610 | 32.64 | 14.45 | 3.32 | 3.48 | n/a | |
|
Wyeth
|
|
n/a | 68,910.588 | 16.92 | 16.20 | 3.47 | 3.42 | 6.56 | |
|
3M Company
|
|
n/a | 57,664.827 | 16.78 | 17.35 | 2.57 | 2.54 | 8.88 | |
|
Solvay SA (ADR)
|
|
n/a | 12,061.013 | 12.15 | n/a | 1.00 | n/a | 4.21 | |
|
Invitrogen Corporation
|
|
n/a | 2,708.846 | n/a | 19.16 | 2.15 | 2.17 | n/a | |
|
GPC Biotech AG (ADR)
|
|
n/a | 711.171 | n/a | n/a | 27.14 | n/a | 7.05 | |
|
Protherics PLC (ADR)
|
|
n/a | 371.558 | n/a | n/a | 10.34 | n/a | 15.01 | |
|
CollaGenex Pharmaceutical, Inc
|
|
n/a | 225.480 | n/a | -6.06 | 14.01 | 9.79 | 10.70 | |
|
Nanophase Technologies Corporation
|
|
n/a | 122.512 | n/a | -27.79 | 14.84 | 13.76 | 7.21 | |
|
Pharmacopeia Drug Discovery, Inc.
|
|
n/a | 84.492 | n/a | -2.50 | 4.39 | 4.72 | 4.46 | |
|
Teijin Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
SR Pharma plc
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Proteros Biostructures GmbH
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
BIOCRATES Life Sciences GmbH
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
GeneData A.G.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Bracco S.p.A.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Evotec OAI AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Tanabe Seiyaku Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
OM PHARMA SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 7,531.6 | 2,412.1 | 9,943.7 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 7,531.6 | 2,412.1 | 9,943.7 |
|
Cost of Revenue
|
3,698.7 | 1,190.1 | 4,888.8 |
|
SG&A Expense
|
1,312.4 | 684.4 | 1,996.8 |
|
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
|
Research & Development
|
1,703.5 | 236.2 | 1,939.7 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | -29.0 | -29.0 |
|
Unusual Expense (Income)
|
30.6 | 0.0 | 30.6 |
| Total Expenses | 6,745.2 | 2,081.8 | 8,827.0 |
|
Operating Income
|
786.4 | 330.3 | 1,116.7 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-108.6 | 0.0 | -108.6 |
|
Other, Net
|
0.0 | -7.5 | -7.5 |
| Income Before Taxes | 677.8 | 322.8 | 1,000.6 |
| Income Taxes | 280.0 | 103.8 | 383.8 |
| Income After Taxes | 397.8 | 219.0 | 616.8 |
| Minority Interest (IS) | -3.3 | -0.4 | -3.7 |
| Equity in Affiliates | -3.5 | 0.0 | -3.5 |
| U.S. GAAP Adjustment | 0.0 | -13.1 | -13.1 |
|
Net Income - Excl. Xord. Items
|
391.0 | 205.5 | 596.5 |
| Discontinued Operations | 0.0 | 431.9 | 431.9 |
|
Net Income - Incl. Xord. Items
|
391.0 | 637.4 | 1,028.4 |
|
Income Avail. to Common
|
391.0 | 637.4 | 1,028.4 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
767.4 | 136.0 | 903.4 |
|
Basic EPS - Excl. Xord. Items
|
0.51 | 1.51 | 0.66 |
|
Basic EPS - Incl. Xord. Items
|
0.51 | 4.69 | 1.14 |
| Full Dilution Adjustment | 10.4 | 0.0 | 10.4 |
| Fully Diluted Shares Outstanding | 833.5 | 136.0 | 969.5 |
|
F.D. EPS - Excl. Xord. Items
|
0.47 | 1.51 | 0.62 |
|
F.D. EPS - Incl. Xord. Items
|
0.47 | 4.69 | 1.06 |
| Dividends Per Common Share | 0.30 | 1.40 | 1.70 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
833.5 | 171.5 | 1,005.0 |
|
ST Investments
|
842.0 | 0.0 | 842.0 |
|
Accounts Receivable
|
3,698.4 | 480.2 | 4,178.6 |
|
Inventory
|
1,867.6 | 261.7 | 2,129.3 |
|
Other Current Assets
|
0.0 | 0.0 | 0.0 |
|
Current Assets
|
7,241.5 | 913.4 | 8,154.9 |
|
Accum D&A
|
0.0 | 0.0 | 0.0 |
|
PPE, Net
|
2,137.3 | 656.8 | 2,794.1 |
| Goodwill & Intangibles | 9,858.6 | 661.9 | 10,520.5 |
| Long Term Investments | 768.2 | 199.4 | 967.6 |
| Other Assets | 0.0 | 2,502.6 | 2,502.6 |
|
Other LT Assets
|
0.0 | 26.7 | 26.7 |
| Total Assets | 20,005.6 | 4,960.7 | 24,966.3 |
| Liabilities | |||
| Accounts Payable | 0.0 | 0.0 | 0.0 |
| Payable/Accrued | 3,207.0 | 0.0 | 3,207.0 |
|
ST Debt
|
737.2 | 0.0 | 737.2 |
|
Curr Port of LTD & Cap Lease Oblg
|
0.0 | 373.5 | 373.5 |
| Other (Current) Liabilities | 0.0 | 0.0 | 0.0 |
|
Current Liab.
|
3,944.2 | 373.5 | 4,317.7 |
|
LT Debt
|
2,554.1 | 38.1 | 2,592.2 |
|
Total LT Debt
|
2,554.1 | 38.1 | 2,592.2 |
| Minority Interest (BS) | 35.0 | 2.5 | 37.5 |
| Deferred Taxes | 652.4 | 77.5 | 729.9 |
|
Other LT Liab.
|
2,241.4 | 1,624.8 | 3,866.2 |
|
Total Liabilities
|
9,427.1 | 2,116.4 | 11,543.5 |
| Shareholders Equity | |||
| Common Stock | 45.7 | 0.0 | 45.7 |
| Additional Paid in Capital | 7,200.0 | 0.0 | 7,200.0 |
| Retained Earnings | 2,997.9 | 0.0 | 2,997.9 |
| Other Equity | 334.9 | 2,844.3 | 3,179.2 |
|
Total Equity
|
10,578.5 | 2,844.3 | 13,422.8 |
|
Total Liab. & Equity
|
20,005.6 | 4,960.7 | 24,966.3 |
|
Shares Outstanding
|
761.3 | 136.0 | 897.3 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 391.0 | 0.0 | 391.0 |
| CF Depreciation | 0.0 | 0.0 | 0.0 |
| CF Deferred Taxes | 0.0 | 0.0 | 0.0 |
| Other Non-Cash Items | 1,563.4 | 0.0 | 1,563.4 |
| Change in Working Capital | -401.7 | 613.3 | 211.6 |
| Total Cash From Operating Activities | 1,552.7 | 613.3 | 2,166.0 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -360.9 | 0.0 | -360.9 |
| Other Investing Cash Flows | -3,767.1 | -856.9 | -4,624.0 |
| Total Cash From Investing Activities | -4,128.0 | -856.9 | -4,984.9 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -208.5 | 0.0 | -208.5 |
| Purchase Or Sale of Stock | 188.0 | 0.0 | 188.0 |
| Purchase and Retirement of Debt | 2,682.5 | 0.0 | 2,682.5 |
| Other Financing Cash Flow | 38.4 | 89.4 | 127.8 |
| Total Cash From Financing Activities | 2,700.4 | 89.4 | 2,789.8 |
| Exchange Rate Effects | 5.3 | 0.3 | 5.6 |
| Net Change in Cash | 130.4 | -154.0 | -23.6 |
| Cash Taxes Paid | 218.6 | 300.0 | 518.6 |
| Cash Interest Paid | 27.4 | 6.3 | 33.7 |